Sanofi Invests €300 Million in Biologics Manufacturing Facility
Sanofi will invest in its Geel, Belgium facility in order to support its pipeline of monoclonal antibodies.
The French drug maker Sanofi plans to invest €300 million (approximately $341.24 million) into expanding its biologics manufacturing facility located in Geel, Belgium, the company said in a April 19, 2016 press announcement.
Sanofi said it plans to expand its existing production capabilities to support its pipeline of monoclonal antibodies. The company will make several upgrades to the facility including new laboratories for quality control and manufacturing. The investment will add more than 8000 m2 of manufacturing floor space to the facility.
Sanofi and its specialty care business, Sanofi Genzyme, have already invested €600 million (approximately $682.68 million) in the Geel site, which began industrial biotech activities in 2001. The site is currently responsible for the global production of a protein therapy for Pompe disease, a rare, genetic muscular disease that can be fatal. The protein therapy is produced using cell cultures in large bioreactors, followed by a purification process.
Source: Sanofi
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
